Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.
Cormedix Inc (CRMD) is a clinical-stage biopharmaceutical company pioneering novel therapies for life-threatening infectious and inflammatory conditions. This news hub provides investors and healthcare stakeholders with essential updates on DefenCath developments, regulatory milestones, and therapeutic pipeline progress.
Access timely announcements including FDA correspondence, clinical trial data, and commercialization strategies for CRMD's catheter lock solutions. Our curated collection features earnings reports, partnership disclosures, and scientific presentations relevant to infection prevention in critical care settings.
Key updates cover therapeutic candidate advancements, intellectual property developments, and market expansion initiatives. Monitor progress in addressing bloodstream infections through CRMD's specialized antimicrobial formulations designed for high-risk patient populations.
Bookmark this page for structured access to verified corporate communications and analysis of how CRMD navigates the complex biopharmaceutical regulatory landscape. Stay informed on developments impacting both patient care standards and long-term therapeutic innovation.
CorMedix (NASDAQ:CRMD) has announced a transformational acquisition of Melinta Therapeutics for $300 million in upfront consideration, including $260M in cash and $40M in CRMD equity. The deal adds seven marketed products to CorMedix's portfolio and is expected to generate pro forma 2025 combined revenues of $305-335 million.
The acquisition brings significant strategic value with expected annual run-rate synergies of $35-45 million and is projected to be accretive to EPS with double-digit accretion in 2026. The deal includes potential additional payments of up to $25 million in regulatory milestones and royalties on REZZAYO™ and MINOCIN® sales.
The transaction is expected to close by September 1, 2025, subject to HSR Act requirements. Melinta's portfolio, which generated $120 million in 2024 revenue, includes key products like REZZAYO™, which has potential peak sales exceeding $200 million in its expanded indication.
CorMedix (NASDAQ:CRMD), a biopharmaceutical company, has announced the pricing of its public offering of 6,604,507 shares of common stock. The offering is expected to generate gross proceeds of approximately $85 million. The company has also granted underwriters a 30-day option to purchase up to an additional 15% of shares.
The offering is expected to close around June 30, 2025, with RBC Capital Markets acting as sole bookrunner. CorMedix plans to use the proceeds for general corporate purposes, including working capital, research and development expenses, and potential strategic transactions.
CorMedix (NASDAQ:CRMD), a biopharmaceutical company, has announced plans for a $85.0 million public offering of common stock. The company will also grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price, less underwriting discounts and commissions.
RBC Capital Markets is serving as the sole bookrunner for the offering. The proceeds will be used for general corporate purposes, including working capital, research and development expenses, and potential strategic transactions such as acquisitions, joint ventures, or collaborations.
CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its participation in the upcoming RBC Capital Markets Global Healthcare Conference. The event will be held in New York from May 20-21, 2025. The company will engage in a fireside chat format presentation scheduled for Wednesday, May 21, 2025, at 3:05 p.m. EDT. A webcast link will be available for interested parties to follow the presentation.
CorMedix (Nasdaq: CRMD), a biopharmaceutical company developing therapeutic products for life-threatening diseases, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, before market opening.
The company will host a corporate update conference call at 8:30am Eastern Time on the same day. Interested parties can join through:
- Domestic call-in: 1-844-676-2922
- International call-in: 1-412-634-6840
- Conference ID: 10198548
- Webcast available via provided link
CorMedix (NASDAQ: CRMD) reports strong preliminary Q1 2025 results with unaudited net revenue of $39.0 million and expected adjusted EBITDA exceeding $22.5 million. The company's cash position stands at $77.5 million as of March 31, 2025.
Due to larger than anticipated orders in late March and improved visibility into customer inventory levels, CorMedix has raised its H1 2025 net sales guidance to $62-70 million. While Q2 2025 sales are expected to be lower than Q1 due to shipment timing, patient utilization is forecast to grow throughout 2025, with H2 shipments projected to exceed H1.
The company plans to begin patient enrollment for DefenCath's Phase 3 study in Total Parenteral Nutrition (TPN) patients in late April. If approved, DefenCath's peak annual sales potential in this indication is estimated at $150-200 million, with a total addressable market of $500-750 million.
CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The event will be held virtually from April 7-10, 2025.
The company's management will engage in a Fireside Chat scheduled for Tuesday, April 8, 2025, at 2:15 p.m. EDT. This participation aligns with CorMedix's ongoing efforts to maintain investor relations and industry presence.
FAQ
What is the current stock price of Cormedix (CRMD)?
What is the market cap of Cormedix (CRMD)?
